Published in Lancet on June 08, 1996
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis (2008) 4.46
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol (1999) 2.29
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ (2010) 1.98
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis (2003) 1.33
Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis (2006) 1.23
The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. PLoS One (2011) 1.23
Anti-retroviral treatment outcomes among older adults in Zomba district, Malawi. PLoS One (2011) 1.18
Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis (2004) 1.18
Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans. Am J Public Health (2001) 1.03
Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in Women. Sex Transm Infect (1999) 0.96
Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. Am J Public Health (2001) 0.94
Age as a prognostic factor in AIDS. Lancet (1996) 0.87
CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 0.87
A challenge for the future: aging and HIV infection. Immunol Res (2010) 0.83
Injecting drug use is associated with a more rapid CD4 cell decline among treatment naïve HIV-positive patients in Indonesia. J Int AIDS Soc (2014) 0.82
Immune activation and paediatric HIV-1 disease outcome. Curr Opin HIV AIDS (2016) 0.79
Time scales of CD4+ T cell depletion in HIV infection. PLoS Med (2007) 0.79
Antiretroviral therapy for human immunodeficiency virus infection in 1997. West J Med (1997) 0.75
Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. AIDS (2017) 0.75
Age as a predictor of progression in HIV infection. Lancet (1996) 0.75
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (1988) 5.45
Mortality before and after HIV infection in the complete UK population of haemophiliacs. UK Haemophilia Centre Directors' Organisation. Nature (1995) 2.88
Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature (1983) 2.59
Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2004) 2.38
Characterisation and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency). Lancet (1984) 2.08
Shaken baby syndrome. Arch Dis Child (2006) 2.07
Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms. Nucleic Acids Res (1984) 2.00
The haemophilic boy in school. Br Med J (1966) 1.99
The treatment of patients who have factor-VIII antibodies. Br J Haematol (1973) 1.94
Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.75
Serum gamma-glutamyltransferase and alkaline phosphatase in rheumatoid arthritis. J Clin Pathol (1982) 1.74
Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J (Clin Res Ed) (1983) 1.58
Delayed diagnosis of Addison's disease. Ann Clin Biochem (1990) 1.57
Septic arthritis in haemophilia. J Bone Joint Surg Br (1993) 1.50
Improving prospects for employment of the haemophiliac. Br Med J (1980) 1.43
A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost (1982) 1.39
Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant. Thromb Haemost (1983) 1.34
Haemophilia B caused by a point mutation in a donor splice junction of the human factor IX gene. Nature (1985) 1.34
A variant of factor 8 related antigen. Br J Haematol (1974) 1.31
Haemophilia Centre Director's annual statistics for 1975. Br J Haematol (1977) 1.30
The management of haemophilia. Practitioner (1970) 1.26
Evidence for existence of at least two types of factor-VIII-associated non-B transfusion hepatitis. Lancet (1978) 1.24
National survey of haemophilia and Christmas disease patients in the United Kingdom. Report on behalf of the Haemophilia Reference Centre directors of the U.K. Lancet (1978) 1.23
Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol (1978) 1.22
Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J (Clin Res Ed) (1983) 1.21
Home treatment in haemophilia: clinical, social and economic advantages. Clin Lab Haematol (1979) 1.19
The sporadic case of haemophilia A. Lancet (1976) 1.16
Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet (1993) 1.16
The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. Br J Haematol (1972) 1.10
Severe allergic pulmonary oedema after plasma transfusion. Br J Haematol (1972) 1.09
Aetiology of seroma formation in patients undergoing surgery for breast cancer. Breast (2000) 1.09
Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol (1971) 1.07
Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure. Gut (1974) 1.06
Serum enzyme changes in diabetic ketoacidosis. Diabetes (1974) 1.06
The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol (1972) 1.05
Proceedings: Transfusion and gel filtration studies in von Willebrand's disease. Br J Haematol (1974) 1.05
Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene. Lancet (1991) 1.04
Home treatment of haemophilia and Christmas disease: five years' experience. Br J Haematol (1977) 1.03
Exercise, factor VIII and the spleen. Br J Haematol (1971) 1.00
Letter: rapid estimation of paracetamol in plasma. J Clin Pathol (1976) 0.98
The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and of a separate concentrate containing factor VII. Br J Haematol (1972) 0.98
A new assay for the measurement of total progressive antithrombin. Br J Haematol (1975) 0.95
Management of the haemophilic child. Arch Dis Child (1972) 0.94
Serum enzymes in colorectal cancer. Cancer (1979) 0.93
Two populations of factor VIII-related antigen in a family with von Willebrand's disease. Br J Haematol (1979) 0.92
Low risk of sexual transmission of hepatitis C virus. J Med Virol (1993) 0.92
Detection of carriers of haemophilia: a 'blind' study. Br J Haematol (1975) 0.92
A less severe form of Haemophilia B Leyden. Nucleic Acids Res (1990) 0.92
Factor VIII gene explains all cases of haemophilia A. Lancet (1992) 0.90
The specificity of antibodies to factor VIII produced in the rabbit after immunization with human cryoprecipitate. Thromb Diath Haemorrh (1973) 0.90
A study of the coagulant properties of Malayan pit-viper venom. Br J Haematol (1965) 0.90
An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS (1990) 0.89
HTLV-III, haemophilia, and blood transfusion. Br Med J (Clin Res Ed) (1985) 0.87
A five year experience of the use of factor IX type DE(I) concentrate for the treatment of Christmas disease of Oxford. Br J Haematol (1975) 0.87
Human immunodeficiency virus variants that escape cytotoxic T-cell recognition. AIDS Res Hum Retroviruses (1992) 0.86
Myocardial infarction in a patient with a circulating anticoagulant. Lancet (1967) 0.86
Carrier detection in hemophilia A: a cooperative international study. I. The carrier phenotype. Blood (1986) 0.85
An optimized semi-automatic rate method for serum glutathione reductase activity and its application to patients with malignant disease. J Clin Pathol (1976) 0.85
Determinants of raised C-reactive protein concentration in type 1 diabetes. QJM (2000) 0.84
Apolipoprotein E phenotyping: a word of caution. Ann Clin Biochem (1991) 0.83
Variation in inhibitor reactivity in acquired haemophilia A with different concentrates. Clin Lab Haematol (2000) 0.82
The effect of erythrocyte ageing on some vitamin and mineral dependent enzymes. Clin Biochem (1979) 0.82
The treatment of patients having spontaneously occurring antibodies to antihaemophilic factor (factor VIII). Thromb Diath Haemorrh (1972) 0.82
A method for detecting factor-VIII clotting activity associated with factor VIII-related antigen in agarose gels. Br J Haematol (1975) 0.81
Transfusion and gel filtration studies in von Willebrand's disease. Br J Haematol (1974) 0.81
Relationships between blood product exposure and immunological abnormalities in English haemophiliacs. Br J Haematol (1985) 0.81
Detection of the prethrombotic state due to procoagulant imbalance. Eur J Haematol (1992) 0.81
Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation. Blood (2000) 0.80
Time from infection with HIV to onset of AIDS in patients with haemophilia in the UK. Stat Med (1990) 0.80
A bichromatic method for total bilirubin with a CentrifiChem 400. Clin Chem (1979) 0.79
Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin. J R Soc Med (1987) 0.79
Detection of microalbuminuria in diabetic patients using a simple latex agglutination test. Clin Chim Acta (1987) 0.79
Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant (1996) 0.78
Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol (1982) 0.78
Automated kinetic assays for routine determination of adenosine deaminase and guanase activities of human serum. Clin Chim Acta (1973) 0.78
Changes in blood coagulation during total hip replacement. Lancet (1978) 0.78
The use of plasma fractions in the treatment of hemophilia and von Willebrand's disease. Prog Hematol (1969) 0.78
Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol (1999) 0.78
Plasma haemostatic factors and diabetic retinopathy. Eur J Clin Invest (1983) 0.78
Pigmentation and busulphan therapy. Br Med J (1966) 0.78
Von Willebrand factor multimer patterns in von Willebrand's disease. Br J Haematol (1983) 0.77
Factor-VIII-related antigen in female haemophilia. Lancet (1973) 0.77
Clinical use of factor IX concentrates. Thromb Haemost (1976) 0.77
Persistent nephrogenic diabetes insipidus, tubular proteinuria, aminoaciduria, and parathyroid hormone resistance following longterm lithium administration. Postgrad Med J (1990) 0.77
HIV infection transmitted through blood product treatment, blood transfusion, and tissue transplantation. Commun Dis Rep CDR Rev (1997) 0.77
Heat stability and kinetic properties of human serum glutathione reductase activity in various disease states. Biochem Med (1981) 0.77
A factor VII concentrate for therapeutic use. Br J Haematol (1980) 0.77